However, the above-mentioned improvement of anti-PD-1+QFM could be significantly attenuated by pre-treatment of 2-NP or FICZ, demonstrating that anti-PD-1+QFM could significantly prevent tumor progression in lung cancer via inhibiting the STAT1-AhR signaling axis. Here, STAT1 is linked to lung carcinoma.